EASD Oct 3 Berlin 2018 pg.75
128 Apabetalone (RVX-208) an epigenetic modifier lowers risk of mACE
in diabetes patients with CVD by affecting monocyte adhesion to
endothelial cells
N.C. Wong, L. Tsujikawa, E. Kulikowski, C. Calosing, S. Wasiak, D. Gilham,
C. Halliday, J.O. Johansson, M. Sweeney, Canada, USA
14:30 - 16:00 Heubner Hall
oP 22 sweetening the endothelium
127 High glucose exposure reduces DnA demethylation of cAmP
response element (CRE) region in enos promoter during
pro-angiogenic CD34+ stem cell differentiation
M. Vinci, V. Vigorelli, J. Resta, S. Genovese, G. Pompilio, Italy
128 Apabetalone (RVX-208) an epigenetic modifier lowers risk of mACE
in diabetes patients with CVD by affecting monocyte adhesion to
endothelial cells
N.C. Wong, L. Tsujikawa, E. Kulikowski, C. Calosing, S. Wasiak, D. Gilham,
C. Halliday, J.O. Johansson, M. Sweeney, Canada, USA
129 Liraglutide improves vascular dysfunction via regulating
cAmP-independent PKA-siRt1/AmPK-PgC1α pathway in perivascular
adipose tissue in obese mice
X. Sun, F. Han, N. Hou, China
130 methylglyoxal driven endothelial dysfunction in hyperglycaemia
targets protein folding, protein synthesis, glycolysis and
gluconeogenesis pathways
N. Rabbani, A. Ashour, Z. Irshad, J. Larkin, M. Xue, P.J. Thornalley, UK,
Saudi Arabia
131 increased hexokinase-2-catalysed entry of glucose into glycolysis:
key driver of metabolic dysfunction in endothelial cells in
hyperglycaemia
P. Thornalley, Z. Irshad, M. Xue, A. Ashour, N. Rabbani, UK, Saudi Arabia
132 Comparative study in various model organisms regarding the
effect of the loss of glyoxalase 1
B. Fuchs, J. Morgenstern, J. Tyedmers, E. Lodd, J. Kroll, D. Schuhmacher,
M. Freichel, P. Nawroth, T. Fleming, Germany